Patheon Inc. Names Interim Head of Pharmaceutical Development Services Unit and Chief Scientific Officer

    RESEARCH TRIANGLE PARK, NC, May 29 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, announced today that it has named Doug
Mendenhall, Ph.D. as interim head of their Pharmaceutical Development Services
Unit and will also carry the interim title of Chief Scientific Officer.
    Dr. Mendenhall is working under contract until such time that a permanent
President is named, but will be retained as an advisor to the company on an
as-needed basis. Dr. Mendenhall is a 35 year veteran in the pharmaceutical
industry, having held executive positions at Abbott, GlaxoSmithKline and most
recently, Merck. He has spent his career leading pharmaceutical and
pre-clinical development teams, contributing to the development and
commercialization of an impressive list of blockbuster drugs. He holds a Ph.D.
in Pharmaceutical Chemistry from the University of Kansas, a Masters in
Medicinal Chemistry from the University of Kansas and Bachelors in Pharmacy
from the University of Washington. He is also lean six sigma certified and a
graduate from the Northwestern University / Kellogg Executive Management
    "Doug brings a wealth of experience, maturity and strategic thinking to
Patheon," said Wes Wheeler, Chief Executive Officer & President. "With Doug on
our Executive Committee, both leading the PDS unit and advising us on
strategy, we will enable further strategic growth of our development services
offering to clients. We look forward to Doug's leadership, as we continue our
search for a permanent President."


    Patheon Inc. (TSX: PTI; is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at or on SEDAR at

    %SEDAR: 00001700E

For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email:; Mr. Eric Evans,
Chief Financial Officer, Tel: (919) 226-3200, Email:

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890